Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients
To evaluate prognostic factors associated with local control and disease-free-survival (DFS) of oligometastatic breast cancer patients treated by percutaneous thermal ablation (PTA).
Materials and Methods
Seventy-nine consecutive patients (54.5 ± 11.2 years old) with 114 breast cancer metastases (28.9 ± 16.1 mm in diameter), involving the lungs, the liver, and/or the bone, were treated using PTA with a curative intent. The goal was to achieve a complete remission in association with systemic chemotherapy and hormonal therapy. We retrospectively evaluated the prognostic factors associated with 1- and 2-year local control and the 1- and 2-year DFS rates.
The 1- and 2-year local control rates were 83.0 and 76.1 %, respectively. Tumor burden was associated with a poorer outcome for local control after PTA (HR 1.027 by additional millimeter, p = 0.026; >4 cm HR 3.90). The 1- and 2-year DFS rates were 54.2 and 30.4 %, respectively. In multivariate analysis, triple-negative histological subtype and increased size of treated metastases were associated with a poorer DFS (HR 2.22; 95 % CI [1.13–4.36]; p = 0.02 and HR 2.43; 95 % CI [1.22–4.82]; p = 0.011, respectively).
PTA is effective for local control of breast cancer oligometastases. Tumor burden >4 cm and triple-negative histological subtype are associated with a poorer outcome.
KeywordsBreast neoplasms Metastases Radiofrequency ablation Microwave ablation Cryotherapy
Percutaneous thermal ablation
Magnetic resonance imaging
Fluoro-deoxy-glucose positron emission tomography
Compliance with Ethical Standards
Conflict of Interest
All authors of the manuscript: Barral Matthias, Aupérin Anne, Hakimé Antoine, Cartier Victoire, Tacher Vania, Otmezguine Yves, Tselikas Lambros, de Baere Thierry, and Deschamps Frédéric have nothing to disclose.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
- 5.Holmes FA, Buzdar AU, Kau S-W, et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED)—the M. D. Anderson experience. Breast Dis. 1994;7:7–20.Google Scholar
- 17.Palussière J, Dixmerias F, Buy X, et al. Interventional radiology procedures in the treatment of bone metastasis. Cancer. 2009;96:1117–26.Google Scholar
- 29.Vogl TJ, Farshid P, Naguib NN, et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. Abdom Imaging. 2015;40(1829–1837):35.Google Scholar
- 33.Palussiere J, Lagarde P, Aupérin A, Deschamps F, Chomy F, de Baere T. Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years’ experience in 87 patients from two centers. Cardiovasc Intervent Radiol. 2015;38:160–6.CrossRefPubMedGoogle Scholar